Oragenics, Inc.

https://www.oragenics.com

Oragenics, Inc. is a development-stage biotechnology company dedicated to developing drugs and therapies focused on the nasal delivery of pharmaceutical medications in neurology. Leveraging cutting-edge intranasal technology and powdered drug formulations, the company aims to address critical unmet medical needs, with a primary focus on concussions. Its mission is to pioneer neurological health solutions that offer tangible improvements for millions of patients, moving beyond mere symptom management. The company's headquarters are located in Sarasota, Florida.

The company's lead product candidate is ONP-002, a first-in-class neurosteroid delivered via a proprietary intranasal system designed for rapid brain absorption. ONP-002 is currently in development for the treatment of mild traumatic brain injury (mTBI), commonly known as concussion. Beyond concussion, Oragenics' proprietary intranasal delivery platform holds potential for broader applications across various neurological conditions, including neurodegenerative diseases and central nervous system disorders. The company pivoted its focus to neurology in January 2024, following the acquisition of neurological assets from Odyssey Health, Inc., having previously engaged in antibiotic research and vaccine development.

In recent developments, Oragenics reported dosing patients in its Phase IIa clinical trial of ONP-002 for mild traumatic brain injury in April 2026, following Human Research Ethics Committee (HREC) approval in Australia in March 2026. Janet Huffman serves as the Chief Executive Officer and Chief Financial Officer. The company is strategically positioning itself to address the significant unmet medical needs in the neurological market, with the global concussion treatment market projected to reach $8.9 billion by 2027.

Latest updates

Oragenics Advances Concussion Trial, Eyes $9B Market

Event summary

  • Oragenics has administered 8 doses to 2 patients in its Phase IIa clinical trial for ONP-002, a treatment for mild traumatic brain injury (mTBI).
  • The trial is enrolling patients based on CT scan findings, symptoms, and hospital admission, with enrollment underway at Mackay Base Hospital in Queensland, Australia.
  • ONP-002 is designed to address neuroinflammation, oxidative stress, and cerebral edema, potentially representing a paradigm shift from symptom management.
  • The global concussion market is projected to reach over $9 billion by 2030, with no currently approved pharmacological treatments.

The big picture

The lack of approved pharmacological treatments for mTBI represents a significant unmet medical need, impacting millions globally and creating a substantial market opportunity. Oragenics’ ONP-002, with its intranasal delivery and targeted mechanism of action, aims to disrupt the current standard of care, which primarily relies on rest and symptom management. The company’s success hinges on demonstrating efficacy and safety in clinical trials, and navigating the regulatory pathway for a novel treatment in a complex neurological condition.

What we're watching

Regulatory Approval
The success of the Phase IIa trial and subsequent Phase IIb trials will be heavily dependent on FDA approval, which remains a significant hurdle given the lack of existing treatments in this space.
Enrollment Pace
The speed of enrollment at Alfred Hospital, and subsequent sites, will be a key indicator of patient and clinician buy-in and the overall viability of the trial design.
Efficacy Data
The data gathered on ONP-002’s impact on neuroinflammation and other biological markers will be crucial in demonstrating a genuine therapeutic effect beyond symptom management, and will influence the likelihood of Phase III progression.

Oragenics Initiates Phase II Trial for Concussion Drug, Signals Market Urgency

Event summary

  • Oragenics initiated a Phase IIa clinical trial for ONP-002, a neurosteroid targeting concussion and mild traumatic brain injury (mTBI), on April 13, 2026.
  • The first patient was dosed at Mackay Hospital in Australia, just days after the site's activation on March 31, 2026.
  • The trial involves 40 patients and will assess safety, tolerability, and feasibility over a 30-day period following dosing within 12 hours of concussion.
  • ONP-002 aims to address neuroinflammation, oxidative stress, and cerebral edema – a departure from current symptom management approaches.
  • The company anticipates submitting an Investigational New Drug (IND) application to the FDA by Q4 2026.

The big picture

The lack of approved pharmacological treatments for concussion represents a significant market opportunity, estimated to reach over $9 billion by 2030. Oragenics’ ONP-002, with its intranasal delivery and targeted mechanism of action, aims to disrupt the current reliance on symptomatic care. However, the company faces the inherent risks associated with clinical trial progression and regulatory approval in a highly competitive pharmaceutical landscape.

What we're watching

Enrollment Velocity
The rapid patient enrollment at Mackay Hospital suggests significant unmet need, but sustained velocity across additional sites will be crucial for timely trial completion.
Regulatory Pathway
The FDA’s response to Oragenics’ planned IND submission in Q4 2026 will dictate the timeline for U.S.-based Phase IIb trials and overall commercialization prospects.
Clinical Efficacy
Demonstrating meaningful clinical efficacy beyond safety and tolerability in the Phase IIa trial will be essential to justify further investment and broader adoption.

Oragenics Restores Compliance, Advances Concussion Drug Trial

Event summary

  • Oragenics filed its Form 10-K for the fiscal year ended December 31, 2025, detailing a year of operational and financial restructuring.
  • The company regained full compliance with NYSE American listing requirements, resolving prior governance issues.
  • A $16.5 million capital raise bolstered the balance sheet, funding Phase IIa clinical trials for ONP-002.
  • Manufacturing operations were relocated from China to a U.S. facility operated by Sterling Pharma Solutions, adhering to FDA cGMP standards.
  • Human Research Ethics Committee (HREC) approval was secured in Australia, enabling patient dosing to begin in the Phase IIa trial of ONP-002.

The big picture

Oragenics' strategic shift reflects a broader trend among smaller biotech firms to prioritize operational efficiency and regulatory compliance after periods of instability. The company's focus on intranasal drug delivery for CNS disorders addresses a significant unmet need in concussion treatment, a market estimated to affect tens of millions globally. The move to U.S.-based manufacturing reduces geopolitical risk and strengthens the company's position with the FDA.

What we're watching

Clinical Execution
The success of the Phase IIa trial in Australia will be critical for demonstrating ONP-002’s efficacy and advancing its development, and patient enrollment rates will be a key indicator of trial progress.
Regulatory Pathway
The company's ability to secure FDA approval for ONP-002 will depend on the Phase IIa data and the effectiveness of their engagement with DUCK FLATS Pharma to prepare an Investigational New Drug (IND) application.
Pipeline Expansion
The pursuit of synergistic CNS asset acquisitions could significantly broaden Oragenics’ pipeline, but the company’s financial resources will constrain the scale and speed of any such acquisitions.

Oragenics Advances Concussion Trial, Eyes Near-Term Patient Enrollment

Event summary

  • Oragenics initiated Phase IIa clinical trial site activation for ONP-002 in Australia, completing the first Site Initiation Visit (SIV).
  • The Phase IIa trial aims to enroll 40 patients across three Australian sites, evaluating ONP-002 for acute concussion and mild traumatic brain injury.
  • The trial's primary endpoints focus on safety, neurocognitive assessments, and patient tolerability.
  • ONP-002 is a first-in-class intranasal neurosteroid, previously demonstrating safety and tolerability in Phase 1 trials with 40 patients.
  • The company expects the remaining two trial sites to complete RGO reviews shortly, enabling patient enrollment.

The big picture

The market for concussion treatments is substantial, estimated at 69 million people globally, and currently underserved by pharmacological interventions. Oragenics' intranasal delivery technology represents a novel approach to brain-targeted therapeutics, potentially bypassing the blood-brain barrier and offering a more direct treatment mechanism. However, the Phase IIa trial results will be crucial in validating this approach and establishing a clear path toward commercialization.

What we're watching

Execution Risk
The speed of RGO reviews at the remaining sites will be critical; delays could push back the anticipated patient enrollment timeline and impact trial progress.
Clinical Efficacy
While Phase I showed safety, the Phase IIa trial’s assessment of preliminary clinical signals will be the first real test of ONP-002’s therapeutic potential in concussion treatment.
Regulatory Pathway
The lack of FDA-approved treatments for concussion creates a potential fast-track pathway, but successful Phase IIa results will be essential to secure further regulatory clearances.

Oragenics Pursues CNS Asset Acquisitions to Bolster Intranasal Platform

Event summary

  • Oragenics is exploring acquisitions of assets focused on brain health, recovery, and neuroprotection.
  • The company's strategy is independent of its existing partnership with Receptor.AI, which focuses on AI-driven CNS drug discovery.
  • ONP-002, Oragenics’ lead candidate, is currently in Phase IIa clinical trials in Australia for concussion and mTBI.
  • Oragenics plans to submit an IND application to the FDA for US-based Phase IIb trials of ONP-002 in 2027.

The big picture

Oragenics’ move to expand its CNS portfolio through acquisition reflects a broader trend among smaller biotech firms seeking to leverage specialized technologies like intranasal drug delivery to address unmet needs in the brain health market. The company's dual strategy of asset acquisition and AI-driven discovery suggests an attempt to accelerate pipeline development while mitigating risk, but the success of this approach will depend on efficient integration and execution.

What we're watching

Acquisition Strategy
The success of Oragenics’ acquisition strategy hinges on identifying assets that genuinely complement its existing platform and offer a clear path to clinical advancement, rather than simply adding complexity.
Clinical Execution
The timing and results of the Phase IIa trial of ONP-002 will be critical in validating the platform and attracting further investment for acquisitions.
Regulatory Pathway
The FDA’s response to Oragenics’ planned IND application in 2027 will significantly influence the company’s ability to advance ONP-002 and any acquired assets into later-stage clinical development.

Oragenics Advances Concussion Treatment to Phase II Trials in Australia

Event summary

  • Oragenics received Human Research Ethics Committee (HREC) approval in Australia to begin Phase IIa clinical trials for ONP-002, a treatment for concussion (mild traumatic brain injury).
  • The trial will enroll 40 patients across three Australian sites, with dosing expected to begin before the end of March 2026.
  • ONP-002 is designed to address neuroinflammation, oxidative stress, and cerebral edema, representing a potential shift from symptom management to active neurological intervention.
  • The global concussion market is projected to reach over $9 billion by 2030, currently lacking FDA-approved pharmacological treatments.

The big picture

The lack of pharmacological treatments for concussion represents a significant unmet medical need, impacting millions globally. Oragenics' ONP-002, with its intranasal delivery and targeted mechanism of action, aims to disrupt the current reliance on symptomatic management. The company’s progress, if successful, could establish a new paradigm in neurological intervention and capture a substantial share of a rapidly growing market.

What we're watching

Clinical Outcomes
The Phase IIa trial's results will be critical in determining whether ONP-002 demonstrates efficacy and safety in a larger patient population, directly impacting the likelihood of FDA approval.
Regulatory Pathway
The speed with which Oragenics can submit an Investigational New Drug (IND) application to the FDA following the Phase IIa data readout will hinge on the trial’s findings and could influence the timeline for U.S. trials.
Market Adoption
The success of ONP-002 will depend on physician adoption and patient willingness to embrace a novel intranasal treatment approach, potentially facing challenges in establishing a new standard of care.

Oragenics Delays Australian Trial Amid Hospital Consolidation

Event summary

  • Oragenics is advancing ONP-002, a neurosteroid for concussion and mTBI, through a Phase 2a clinical trial in Australia.
  • The company has $16.5 million in funding and a clean balance sheet, fully funding the Phase 2a trial.
  • Regulatory approvals for the trial have been delayed due to a merger of five hospitals in Victoria, Australia, forming Bayside Health.
  • The global concussion market is projected to reach over $9 billion by 2030, with ONP-002 potentially being the first commercial treatment.
  • Oragenics moved drug manufacturing from China to the United States, partnering with Sterling Pharma Solutions.

The big picture

Oragenics' lead candidate, ONP-002, addresses a significant unmet medical need in the $9 billion concussion market. The company's reliance on a single clinical trial in Australia introduces concentration risk, and the hospital consolidation highlights the challenges of navigating healthcare systems undergoing structural change. The move to U.S.-based manufacturing reduces geopolitical risk but introduces new operational dependencies.

What we're watching

Governance Dynamics
The timing and impact of Bayside Health's internal governance processes will dictate the resumption of the Phase 2a trial, potentially affecting Oragenics' 2026 milestones.
Regulatory Headwinds
The FDA's assessment of ONP-002's IND application will be crucial for future U.S. trials, and any delays could impact the overall development timeline.
Execution Risk
The success of the Phase 2a trial hinges on patient enrollment and adherence to the protocol, which could be impacted by the delayed start and the complexity of the patient criteria.

Oragenics Enlists Regulatory Expert for Concussion Therapy Advance

Event summary

  • Oragenics has engaged DUCK FLATS Pharma to support FDA IND readiness and clinical trial design for its ONP-002 concussion therapy.
  • DUCK FLATS Pharma has been involved in the development and approval of approximately 40 drug programs, including intranasal therapies like Narcan® and neffy®.
  • The collaboration aims to align Oragenics’ Phase 2a clinical trial in Australia with its U.S. regulatory strategy.
  • The global concussion market is projected to reach over $9 billion by 2027, and the nasal drug delivery market is expected to reach $125+ billion by 2030.
  • ONP-002 is currently in Phase 2a clinical trials in Australia, with U.S. Phase IIb trials planned.

The big picture

Oragenics’ partnership with DUCK FLATS Pharma highlights the increasing complexity and cost of drug development, particularly for neurological therapies. The collaboration underscores the strategic importance of regulatory expertise in securing FDA approval and accelerating market access. The company is attempting to capitalize on a large, underserved market—concussions—but faces significant competition from other potential therapies and delivery methods.

What we're watching

Regulatory Risk
The success of ONP-002 hinges on navigating FDA approval, and DUCK FLATS Pharma’s experience will be critical, but their past successes don’t guarantee a smooth path.
Clinical Execution
The alignment of Australian and U.S. clinical trials will be a key indicator of Oragenics’ ability to manage a complex, global development program.
Market Adoption
While the concussion market is substantial, the lack of existing therapies doesn’t guarantee rapid adoption of ONP-002 if approved; physician and patient acceptance will be vital.

Oragenics to Network at SCOPE Summit Ahead of Concussion Trial

Event summary

  • Oragenics will participate in the SCOPE Summit 2026, February 2–5 in Orlando, Florida.
  • The company aims to engage with clinical research leaders before commencing Phase 2a trials of ONP-002 in Australia.
  • SCOPE Summit attracts over 1,200 companies from 30 countries, focusing on clinical operations and innovation.
  • ONP-002 is a lead candidate targeting concussion and mild traumatic brain injury, a market with significant unmet need.

The big picture

The SCOPE Summit represents a key networking opportunity for Oragenics as it advances its lead candidate for concussion treatment. The company's focus on intranasal delivery for neurological disorders positions it within a growing area of therapeutic innovation, but clinical trial success remains the critical determinant of long-term value. The summit's emphasis on generative AI and RBQM suggests a broader industry shift towards data-driven clinical operations, which Oragenics will need to adapt to.

What we're watching

Trial Execution
The value of Oragenics' participation in SCOPE hinges on whether they can glean actionable insights to optimize the Phase 2a trial design and execution, given the complexity of neurological research.
Regulatory Pathway
The success of ONP-002 will depend on navigating regulatory hurdles, and the company's engagement with regulatory affairs experts at SCOPE could signal an attempt to proactively address potential challenges.
Competitive Landscape
The summit provides an opportunity to assess the competitive landscape for concussion treatments and gauge the perceived differentiation of Oragenics' intranasal delivery platform.

Oragenics to Present at Investor Summit Amidst Concussion Treatment Pursuit

Event summary

  • Oragenics will present at the Sequire Investor Summit in San Juan, Puerto Rico, from January 20th to 22nd, 2026.
  • The company is focused on advancing ONP-002, a potential first-in-class treatment for concussion and mild traumatic brain injury.
  • Puerto Rico's favorable tax environment attracts significant family offices and investors.
  • Oragenics is currently in Phase 2a clinical trials in Australia for ONP-002, with Phase 2b trials planned for the U.S.

The big picture

Oragenics' focus on concussion treatment addresses a significant unmet medical need, a market estimated to be worth billions annually. The company's reliance on intranasal delivery technology represents a potential differentiator, but the clinical trial results will be the primary driver of investor sentiment. The choice of the Sequire Investor Summit, given Puerto Rico's unique tax structure, suggests a deliberate strategy to access a specific investor pool.

What we're watching

Clinical Progress
The success of the ongoing Phase 2a trials in Australia will be critical in determining the viability of ONP-002 and influencing the timeline for the planned Phase 2b trials in the U.S.
Investor Interest
The company's presence at the Sequire Investor Summit, given Puerto Rico's tax-advantaged investor base, suggests a targeted effort to secure funding and may indicate the company's need for additional capital.
Market Dynamics
The lack of approved therapies for concussion creates a significant market opportunity, but the competitive landscape will likely intensify as other companies pursue similar treatments.
CID: 665